NYSE:GSK - GlaxoSmithKline Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$41.25 +0.01 (+0.02 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$41.25
Today's Range$41.25 - $41.62
52-Week Range$36.41 - $42.36
Volume2.51 million shs
Average Volume2.09 million shs
Market Capitalization$102.32 billion
P/E Ratio13.05
Dividend Yield5.72%
Beta0.76
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Otrivin, Panadol, Fenistil, Lamisil, Breathe Right, Stiefel, Excedrin, Physiogel, Polident, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. It has a discovery collaboration agreement with Kymera Therapeutics LLC; a collaboration agreement with InSysBio LLC to develop quantitative systems pharmacology model of asthma; a strategic collaboration with NeuroMetrix, Inc. to develop and market Quell technology; and strategic alliance with Merck KGaA to jointly develop and commercialize M7824 (bintrafusp alfa), an investigational bifunctional fusion protein immunotherapy. GlaxoSmithKline plc also has a joint research collaboration with Fimbrion Therapeutics Inc. to develop a small molecule candidate for the treatment and prevention of urinary tract infections. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone44-20-8047-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$41.14 billion
Cash Flow$4.1583 per share
Book Value$1.98 per share

Profitability

Net Income$4.84 billion

Miscellaneous

Employees99,349
Outstanding Shares2,480,600,000
Market Cap$102.32 billion
Next Earnings Date4/24/2019 (Estimated)
OptionableOptionable

GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline announced a quarterly dividend on Friday, February 8th. Shareholders of record on Friday, February 22nd will be given a dividend of $0.597 per share on Thursday, April 11th. This represents a $2.39 annualized dividend and a yield of 5.79%. The ex-dividend date is Thursday, February 21st. This is an increase from GlaxoSmithKline's previous quarterly dividend of $0.49. View GlaxoSmithKline's Dividend History.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) posted its quarterly earnings results on Wednesday, February, 6th. The pharmaceutical company reported $0.79 earnings per share for the quarter, beating analysts' consensus estimates of $0.70 by $0.09. The pharmaceutical company earned $10.55 billion during the quarter, compared to analysts' expectations of $9.85 billion. GlaxoSmithKline had a net margin of 11.45% and a return on equity of 160.39%. View GlaxoSmithKline's Earnings History.

When is GlaxoSmithKline's next earnings date?

GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, April 24th 2019. View Earnings Estimates for GlaxoSmithKline.

What price target have analysts set for GSK?

18 brokers have issued 1-year target prices for GlaxoSmithKline's shares. Their predictions range from $36.95 to $47.00. On average, they anticipate GlaxoSmithKline's share price to reach $41.39 in the next twelve months. This suggests a possible upside of 0.3% from the stock's current price. View Analyst Price Targets for GlaxoSmithKline.

What is the consensus analysts' recommendation for GlaxoSmithKline?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 1 sell rating, 13 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GlaxoSmithKline.

Has GlaxoSmithKline been receiving favorable news coverage?

Headlines about GSK stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GlaxoSmithKline earned a coverage optimism score of 1.3 on InfoTrie's scale. They also gave news articles about the pharmaceutical company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the stock's share price in the next few days.

Who are some of GlaxoSmithKline's key competitors?

What other stocks do shareholders of GlaxoSmithKline own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GlaxoSmithKline investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Johnson & Johnson (JNJ), Cisco Systems (CSCO), General Electric (GE), Bank of America (BAC), Intel (INTC), Exxon Mobil (XOM) and Gilead Sciences (GILD).

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the folowing people:
  • Ms. Emma N. Walmsley, CEO & Director (Age 49)
  • Mr. Simon P. Dingemans, CFO & Exec. Director (Age 55)
  • Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 56)
  • Mr. Jack Bailey, Pres of US Pharmaceuticals
  • Ms. Karenann K. Terrell, Chief Digital & Technology Officer (Age 57)

Who are GlaxoSmithKline's major shareholders?

GlaxoSmithKline's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (0.71%), Fisher Asset Management LLC (0.57%), Bank of America Corp DE (0.31%), Northern Trust Corp (0.11%), Macquarie Group Ltd. (0.10%) and Bank of New York Mellon Corp (0.09%). View Institutional Ownership Trends for GlaxoSmithKline.

Which major investors are selling GlaxoSmithKline stock?

GSK stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Thrivent Financial for Lutherans, Bank of America Corp DE, Sphera Funds Management LTD., Schafer Cullen Capital Management Inc, Confluence Investment Management LLC, Amundi Pioneer Asset Management Inc. and BlackRock Inc.. View Insider Buying and Selling for GlaxoSmithKline.

Which major investors are buying GlaxoSmithKline stock?

GSK stock was purchased by a variety of institutional investors in the last quarter, including Boston Partners, Norges Bank, Two Sigma Investments LP, Millennium Management LLC, Eversept Partners LP, South Texas Money Management Ltd., Diamond Hill Capital Management Inc. and Ferguson Wellman Capital Management Inc.. View Insider Buying and Selling for GlaxoSmithKline.

How do I buy shares of GlaxoSmithKline?

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GlaxoSmithKline's stock price today?

One share of GSK stock can currently be purchased for approximately $41.25.

How big of a company is GlaxoSmithKline?

GlaxoSmithKline has a market capitalization of $102.32 billion and generates $41.14 billion in revenue each year. The pharmaceutical company earns $4.84 billion in net income (profit) each year or $3.16 on an earnings per share basis. GlaxoSmithKline employs 99,349 workers across the globe.

What is GlaxoSmithKline's official website?

The official website for GlaxoSmithKline is http://www.gsk.com.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]


MarketBeat Community Rating for GlaxoSmithKline (NYSE GSK)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  542 (Thanks for Voting!)
Underperform Votes:  900 (Thanks for Voting!)
Total Votes:  1,442
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe GSK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GSK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel